Last reviewed · How we verify

Ocaliva — Competitive Intelligence Brief

Ocaliva (Ocaliva) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

phase 2 G-protein coupled bile acid receptor 1, Bile acid receptor Other Small molecule Live · refreshed every 30 min

Target snapshot

Ocaliva (Ocaliva) — Universitaire Ziekenhuizen KU Leuven.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ocaliva TARGET Ocaliva Universitaire Ziekenhuizen KU Leuven phase 2 G-protein coupled bile acid receptor 1, Bile acid receptor
Cholbam Cholbam Mirum Pharmaceuticals, Inc. marketed G-protein coupled bile acid receptor 1, Bile acid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ocaliva — Competitive Intelligence Brief. https://druglandscape.com/ci/ocaliva. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing